Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)

You'll soon see patients on Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC).

It's related to gefitinib (Iressa). These two drugs are intended to target growth factors that stimulate tumor growth.

The difference is that Tarceva extends life two months longer than placebo. Iressa is unable to show any improved survival.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote